The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1202
ISSUE1202
February 14, 2005
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis
February 14, 2005 (Issue: 1202)
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.